Stock Market News2 weeks ImmuCell Posts Y/Y Q4 Earnings Growth, Awaits FDA Approval for Re-Tain Zacks
ImmuCell posts 52% y/y sales growth in Q4. It improves margins and eyes FDA approval for Re-Tain to drive expansion.
XImmuCell posts 52% y/y sales growth in Q4. It improves margins and eyes FDA approval for Re-Tain to drive expansion.
X